Lexie B2 Plus vs Resound Vivia 9 60S microRIE

The Lexie B2 Plus is a mid-priced OTC hearing aid that earns an A grade with a SoundScore of 4.4/5, placing it in the top 9% of OTC devices tested in our lab. At $899, this behind-the-ear style device delivers strong performance in several key areas while showing some limitations worth considering. In our testing, the Lexie B2 Plus excels in speech clarity for quiet environments, scoring a strong 4.3/5—significantly above the OTC category average by 1.49 points. Own-voice comfort is a particular standout at 4.8/5, well above the category average by 2.29 points, meaning wearers are unlikely to experience the hollow or booming quality of their own voice that can make some hearing aids uncomfortable. Speech in noise performance scores 2.1/5, which is above the OTC category average by 0.58 points but remains mixed in absolute terms—typical for this device class. Music streaming scores 2.6/5, similarly above average by 0.68 points while remaining modest overall. Feedback handling at 2.8/5 falls below the category average by 1.74 points, which may require attention during phone calls or when wearing hats. The Lexie B2 Plus is a solid choice for users prioritizing speech clarity in quieter settings and natural own-voice comfort. It features rechargeable batteries and streaming compatibility with both iPhone and Android devices. This two-time Expert's Choice Award winner (2023, 2024) competes against devices like the higher-scoring Sony CRE-E10 in its price range, but offers a compelling balance of comfort and core speech performance.

The Resound Vivia 9 60S microRIE is a premium prescription behind-the-ear hearing aid released in 2025, currently available at $3,798. In HearAdvisor's lab testing, it earned a B grade with a SoundScore of 3.9/5, ranking #27 of 36 prescription hearing aids tested. This device demonstrates a mixed performance profile in our testing. Own-voice comfort is a notable strength, scoring 3.4/5—a solid result that sits 0.65 points above the category average, which may appeal to users sensitive to the hollow or boomy sound of their own speech. Speech clarity in quiet environments also performs well at 3.4/5, slightly above the category average. However, the Vivia 9 shows significant limitations in challenging listening situations. Speech in noise scored just 1.1/5, falling 0.81 points below the prescription hearing aid average—a substantial gap that suggests difficulty in restaurants, group conversations, or other noisy environments. Feedback handling, while strong in absolute terms at 4.2/5, still lands 0.51 points below what we typically see from prescription devices. Music streaming quality is mixed at 2.6/5, essentially matching the category average. At this premium price point, the Vivia 9 faces stiff competition. Several same-priced alternatives, including the Phonak Sphere Infinio and Oticon Intent, achieved notably higher overall scores in our testing. Consumers prioritizing noise performance may want to explore these options or consider lower-priced alternatives like the Sennheiser All Day Clear that delivered stronger overall results in our lab.